NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Educational Programs and Avenova Product Promotions
28 Juin 2023 - 12:50PM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality eyecare, skincare and
wound care products, announces that it will be sponsoring dry eye
educational programs and offering special promotions on its
Avenova®-branded eyecare products to customers and eyecare
professionals throughout July in support of National Dry Eye
Awareness Month.
“Dry eye can be attributed to many factors such as exposure to
air pollution and indoor heating and cooling, wearing contact
lenses and even staring for too long at computer or smartphone
screens,” said Justin Hall, NovaBay CEO. “Over the years we have
consistently heard from patients and eyecare professionals alike
that managing chronic dry eye can be a challenge. Recognizing that
a single approach may not be sufficient to gain and sustain relief
from the symptoms of dry eye, NovaBay now offers a full line of
best-in-class products under the Avenova brand.
“Throughout July we will be reaching customers and eyecare
professionals through advertising, social media, email and direct
mail campaigns, and tapping into the expertise of our Optometry and
Ophthalmology Advisory Boards and other influencers to raise
awareness about dry eye and offer solutions to manage this
condition,” he added.
Customers ordering on Avenova.com will receive a 20% discount
plus free shipping on the full line of Avenova-branded products,
including additional savings for those using the ‘subscribe and
save’ function. This promotion allows customers to replenish their
Avenova supplies during the summer months and provides special
pricing to encourage customers to try additional Avenova
products.
Eyecare professionals are invited to participate in the Woo
University’s online course “Eyelid Hygiene From Office Education
and Product Dispensing to Increasing Patient Compliance at Home” on
Thursday, July 13, 2023 from 5:30-6:30 p.m. Pacific time. The
COPE-accredited, CE-credit course is being sponsored by Avenova and
will be moderated by Jennifer Stewart, OD with featured speaker
Elise Kramer, OD. This course aims to educate practitioners how to
increase compliance with lid hygiene for patients by offering
revenue products in their office and/or ensuring patients have
access to recommended products once they leave the office. The
course will also discuss the importance of eyelid health for
contact lens patients and present studies showing discomfort as the
leader of contact lens dropout. Registration is available here.
NovaBay offers best-in-class Avenova-branded products for each
step of the standard dry-eye treatment regimen, including Avenova
spray, the No. 1 doctor-recommended lid and lash cleanser,
lubricating eye drops for instant relief, a warm eye compress to
soothe, an antioxidant-rich dietary supplement with omega-3 oils
and the i-Chek to monitor eyelid health.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
eyecare consumers through online distribution channels such as
Amazon. DERMAdoctor® offers more than 30 dermatologist-developed
skincare products through the DERMAdoctor website, well-known
traditional and digital beauty retailers, and international
distributors. NovaBay also manufactures and sells effective, yet
gentle and non-irritating wound care products. The PhaseOne® brand
is distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230628920628/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024